Abstract:BACKGROUND Gastric cancer (GC) is a highly aggressive malignancy with a heterogeneous nature, which makes prognosis prediction and treatment determination difficult. Inflammation is now recognized as one of the hallmarks of cancer and plays an important role in the aetiology and continued growth of tumours. Inflammation also affects the prognosis of GC patients. Recent reports suggest that a number of inflammatory-related biomarkers are useful for predicting tumour prognosis. However, the importance of inflammatory-related biomarkers in predicting the prognosis of GC patients is still unclear. AIM To investigate inflammatory-related biomarkers in predicting the prognosis of GC patients. METHODS In this study, the mRNA expression profiles and corresponding clinical information of GC patients were obtained from the Gene Expression Omnibus (GEO) database (GSE66229). An inflammatory-related gene prognostic signature model was constructed using the least absolute shrinkage and selection operator Cox regression model based on the GEO database. GC patients from the GSE26253 cohort were used for validation. Univariate and multivariate Cox analyses were used to determine the independent prognostic factors, and a prognostic nomogram was established. The calibration curve and the area under the curve based on receiver operating characteristic analysis were utilized to evaluate the predictive value of the nomogram. The decision curve analysis results were plotted to quantify and assess the clinical value of the nomogram. Gene set enrichment analysis was performed to explore the potential regulatory pathways involved. The relationship between tumour immune infiltration status and risk score was analysed via Tumour Immune Estimation Resource and CIBERSORT. Finally, we analysed the association between risk score and patient sensitivity to commonly used chemotherapy and targeted therapy agents. RESULTS A prognostic model consisting of three inflammatory-related genes (MRPS17, GUF1, and PDK4) was constructed. Independent prognostic analysis revealed that the risk score was a separate prognostic factor in GC patients. According to the risk score, GC patients were stratified into high- and low-risk groups, and patients in the high-risk group had significantly worse prognoses according to age, sex, TNM stage and Lauren type. Consensus clustering identified three subtypes of inflammation that could predict GC prognosis more accurately than traditional grading and staging. Finally, the study revealed that patients in the low-risk group were more sensitive to certain drugs than were those in the high-risk group, indicating a link between inflammation-related genes and drug sensitivity. CONCLUSION In conclusion, we established a novel three-gene prognostic signature that may be useful for predicting the prognosis and personalizing treatment decisions of GC patients.

Identification of BANF1 as a novel prognostic biomarker in gastric cancer and validation via in-vitro and in-vivo experiments

Identification of Significant Biomarkers and Pathways Associated with Gastric Carcinogenesis by Whole Genome-Wide Expression Profiling Analysis

Identification Oftyrobpandc1qbas Two Novel Key Genes with Prognostic Value in Gastric Cancer by Network Analysis

ASF1b is a Novel Prognostic Predictor Associated with Cell Cycle Signaling Pathway in Gastric Cancer

Family with sequence similarity 153 member B as a potential prognostic biomarker of gastric cancer.

BANF1 is a novel prognostic biomarker linked to immune infiltration in head and neck squamous cell carcinoma

Integrated Single-Cell RNA-Sequencing Analysis of Gastric Cancer Identifies FABP1 as a Novel Prognostic Biomarker

Bioinformatics Identification of Therapeutic Gene Targets for Gastric Cancer

Identification of an Immune Gene-Associated Prognostic Signature and Its Association With a Poor Prognosis in Gastric Cancer Patients

Integrated Profiling Identifies SLC5A6 and MFAP2 As Novel Diagnostic and Prognostic Biomarkers in Gastric Cancer Patients

Identification of Potential Biomarkers Associated with Prognosis in Gastric Cancer via Bioinformatics Analysis

A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer

Identification and validation of key genes in gastric cancer: insights from in silico analysis, clinical samples, and functional assays

In Silico Insights Reveal Fibronectin 1 as a Theranostic Marker in Gastric Cancer

Identifying Novel Cell Glycolysis-Related Gene Signature Predictive of Overall Survival in Gastric Cancer

Identification of a 3-Gene Model as Prognostic Biomarker in Patients With Gastric Cancer

Identification of novel tumor microenvironment-associated genes in gastric cancer based on single-cell RNA-sequencing datasets

Identification of functional genes regulating gastric cancer progression using integrated bioinformatics analysis

Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer

Identification of a novel inflammatory-related gene signature to evaluate the prognosis of gastric cancer patients

Development and Validation of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and the Immune Microenvironment in Gastric Cancer